Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
about
Current prospects for the fluoroquinolones as first-line tuberculosis therapyDiscovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA SynthetaseOptimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of TuberculosisDiscovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screenTwo-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinumExpression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolonesPharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisPropensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant TuberculosisA computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatmentInsights into the pharmacokinetic properties of antitubercular drugs.Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysisNovel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosisPharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis.In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteriaComparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates.Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine modelIn vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBImpact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection modelEffects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacinIn silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatmentPharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosisEfficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains.Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacinAccumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program.Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of ActionContribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.The chemotherapy of tuberculosis: past, present and future.
P2860
Q26823843-DE3D8DA3-169B-4038-99EC-D33CCE4F40A5Q27644677-81C2998A-6B6E-4381-B867-960AD25AB444Q27680342-23F11FF2-3C13-443C-9617-246485C73A79Q28478254-AFE6C8F8-7419-4198-BDC1-60A2E3D651E6Q28478890-98451918-A35F-49B0-A71E-76AFF9660BC9Q28484902-42780F69-4ED3-42C7-A0CB-EE30EA772EBEQ28542435-5360B8B8-B3EF-422B-92E8-B8DB446E23A1Q28551033-9F390EEA-40D4-4620-A3F0-BC39B2765A1CQ28649754-63A590B6-9D3A-4AAE-9295-62BE0DAFF3FEQ30251497-E8F7C9F1-29EB-45DC-AB02-124DE7A17262Q30383012-2E73C27E-9517-44A9-8949-F288E4BBDA81Q30411703-9B5F5C39-EEC0-4955-B916-FD4884F95AAEQ30834393-0D473D43-C1A3-472F-9219-DD77E80FFC2CQ33581286-0C3F4F6B-0589-4602-B513-DBE8F01ED6C7Q33623003-D0AF43AD-8053-49E4-A0B7-C696FEAA9FDFQ33798492-C2E1432D-389A-4F7E-AE14-4F123AD40C33Q33826405-606D3F81-33B0-4649-AFBD-BC67935C0182Q34046259-268BA0A0-58AC-4690-B388-F8D9C10381E8Q34290003-4D1237C8-87B4-4AB9-A3AE-25B78A944E44Q34591451-0EA3EB49-3461-4659-A9D6-C02636724184Q34922554-91990F18-9969-4DAD-8AB6-707D5E94C865Q35033562-BC2E1BB2-E798-4D5F-9D9A-9B0C05B10A1AQ35169124-B6E15C2B-A5AA-4B36-82DC-23901B5FE07FQ35197257-057BC00B-0BEF-49A5-A43C-B20D87393A79Q35746184-71F3A622-8B1F-4963-A3AA-32F37511A8F2Q35806445-0046DBA9-2FF7-4B09-A80A-C34500768309Q35864589-7FAF20B1-CD28-40AF-8062-BAD070C1A535Q35912661-FF78DAB0-EB7F-4FA9-BF83-97968B229C61Q35960910-457C0DAA-FDC2-4252-B0CF-B0E9D5AD7B39Q36075800-484C1D0B-8087-42FD-836F-E068F768C9A3Q36086373-3323A19B-B78E-4940-8C0E-73FEC5505573Q36347436-1DA6A070-595F-4377-B9BF-B93589B4A84BQ36482760-6859435D-2F9D-40B2-B412-9C7762896956Q36681757-DD4E3593-5CB5-4DB2-802B-707EC40A7C4CQ36728692-D060E208-95B0-46C8-BA5E-B802FBA4EFA0Q36905756-E9B5A9CD-5ED8-4361-8FD9-5739C0DC73DEQ36949454-E68B58EC-3FAA-4134-8836-8D2EAC89BAE0Q37023216-480B0828-74FB-42DB-9B4D-7D57D1A411E7Q37074826-3DFD2615-C295-4481-83B2-8E4082CAC86CQ37076746-F8616A38-0DA0-4D5C-9B73-C08909F51977
P2860
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Moxifloxacin, ofloxacin, sparf ...... best predict in vivo efficacy.
@ast
Moxifloxacin, ofloxacin, sparf ...... best predict in vivo efficacy.
@en
type
label
Moxifloxacin, ofloxacin, sparf ...... best predict in vivo efficacy.
@ast
Moxifloxacin, ofloxacin, sparf ...... best predict in vivo efficacy.
@en
prefLabel
Moxifloxacin, ofloxacin, sparf ...... best predict in vivo efficacy.
@ast
Moxifloxacin, ofloxacin, sparf ...... best predict in vivo efficacy.
@en
P2093
P2860
P356
P1476
Moxifloxacin, ofloxacin, sparf ...... best predict in vivo efficacy.
@en
P2093
B L Suresh
B N Mahesh
Parvinder Kaur
R Jayashree
Radha K Shandil
Ramesh Jayaram
Sheshagiri Gaonkar
Sowmya Bharath
V Balasubramanian
Vrinda Nandi
P2860
P304
P356
10.1128/AAC.00414-06
P407
P577
2006-12-04T00:00:00Z